关注
Robert Gray
Robert Gray
Professor of Biostatistics, Havard School of Public Health
在 jimmy.harvard.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
A proportional hazards model for the subdistribution of a competing risk
JP Fine, RJ Gray
Journal of the American statistical association 94 (446), 496-509, 1999
134771999
Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer
A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati, ...
New England Journal of Medicine 355 (24), 2542-2550, 2006
74212006
A class of K-sample tests for comparing the cumulative incidence of a competing risk
RJ Gray
The Annals of statistics, 1141-1154, 1988
52211988
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 379 (9814), 432-444, 2012
22132012
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 379 (2), 111-121, 2018
20692018
Prospective validation of a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
15202015
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
S Adams, RJ Gray, S Demaria, L Goldstein, EA Perez, LN Shulman, ...
Journal of clinical oncology 32 (27), 2959, 2014
13802014
Annual hazard rates of recurrence for breast cancer after primary therapy.
T Saphner, DC Tormey, R Gray
Journal of clinical oncology 14 (10), 2738-2746, 1996
10261996
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system
CA Hudis, WE Barlow, JP Costantino, RJ Gray, KI Pritchard, ...
Journal of Clinical Oncology 25 (15), 2127-2132, 2007
8172007
Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers
S Loi, D Drubay, S Adams, G Pruneri, PA Francis, M Lacroix-Triki, ...
Journal of clinical oncology 37 (7), 559, 2019
6812019
Flexible methods for analyzing survival data using splines, with applications to breast cancer prognosis
RJ Gray
Journal of the American Statistical Association 87 (420), 942-951, 1992
6661992
Computing an exact confidence interval for the common odds ratio in several 2× 2 contingency tables
CR Mehta, NR Patel, R Gray
Journal of the American Statistical Association 80 (392), 969-973, 1985
5711985
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast
LJ Solin, R Gray, FL Baehner, SM Butler, LL Hughes, C Yoshizawa, ...
Journal of the National Cancer Institute 105 (10), 701-710, 2013
5682013
Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group
A Recht, R Gray, NE Davidson, BL Fowble, LJ Solin, FJ Cummings, ...
Journal of Clinical Oncology 17 (6), 1689-1689, 1999
5571999
Calculation of polychotomous logistic regression parameters using individualized regressions
CB Becg, R Gray
Biometrika 71 (1), 11-18, 1984
5421984
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.
T Saphner, DC Tormey, R Gray
Journal of Clinical Oncology 9 (2), 286-294, 1991
5301991
Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC# 704865) in patients with advanced non-squamous non-small cell lung cancer …
AB Sandler, R Gray, J Brahmer, A Dowlati, JH Schiller, MC Perry, ...
Journal of Clinical Oncology 23 (16_suppl), LBA4-LBA4, 2005
5242005
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern …
SS Ramalingam, SE Dahlberg, CJ Langer, R Gray, CP Belani, ...
J Clin Oncol 26 (1), 60-65, 2008
4602008
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer
EG Mansour, R Gray, AH Shatila, CK Osborne, DC Tormey, KW Gilchrist, ...
New England Journal of Medicine 320 (8), 485-490, 1989
4541989
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ...
New England journal of medicine 380 (25), 2395-2405, 2019
4452019
系统目前无法执行此操作,请稍后再试。
文章 1–20